u/canada_coverage

Is that baseline drawn by the software or by hand?

I would not blame the sample yet. Everything you have described is consistent with the column rather than the vial.

The no-timing-restriction thing is the part I would care about most in practice, and it barely gets mentioned here.

What wavelength, and what was the gradient?

Adding one practical thing — run the blank. It answers this before anyone has to argue about it.

Milligram comparisons across molecule classes are meaningless. Potency is a property of the molecule at its receptor, not of the number on the label.

appeal in writing even when they say a call is enough

Province added to the title. Coverage is provincial and the thread could not be answered without it.

Left up. It distinguishes a rejected claim from a denied authorization, which most posts here do not.

A rejected claim at the pharmacy counter and a denied authorization are different events with different remedies. The first can be an administrative or quantity issue; the second is a determination you can appeal.

research-use-only material is not approved for human use

reproducibility beats resolution if you only get one of them

The three questions to ask before ordering anything from the long tail of a catalogue.

What exactly is it — catalogue number or sequence, not a common name, because several common names map to more than one molecule. How was identity established — mass against theoretical, ideally, rather than a bare purity figure. What are the storage conditions, stated specifically, with a state and a duration attached.

Then two commercial questions that save time: is this a stocked line or made to order, and what is the lead time in writing. All five are one email, and the shape of the reply tells you a great deal before any material moves.

the tolerability profile reads broadly similar to the class

Plan and policy numbers redacted from the screenshot above.

the column has a history and it shows in the peak shape

the manufacturing story is genuinely different from the injectables

Not convinced. Oral semaglutide is a peptide formulated with an absorption enhancer; the comparison you are making does not hold.

That criterion is from the previous plan year. The current bulletin has different wording.

What has been documented as tried, and for how long?

Small fix — external review is independent of the plan. The second-level internal appeal is not.

a template letter that quotes their own criteria back is the strongest one

oral semaglutide is a peptide with an absorption enhancer, this is not that

214nm sees the peptide bond, 280nm sees the aromatics

report the method or do not report the number

This. A shoulder that does not baseline-resolve is a question, not a quantity.

I would not extrapolate a mechanism from a model system to a person in one step, which is what that comment does.

Documented eighteen months of what had been tried in a one-page table. That table was the appeal.

Correction: that study was in rodents. Worth stating explicitly since the thread has been reading it as clinical.

That criterion is from the previous plan year. The current bulletin has different wording.

Left up. It distinguishes a rejected claim from a denied authorization, which most posts here do not.

Pharmacy staff name removed. The pharmacy can stay in a pricing post.

reproducibility beats resolution if you only get one of them

quiet_reader_99 is right — the integration choice is a decision and it should be stated alongside the result.

prior authorisation criteria change every plan year

Correction: that is a formulary exclusion, not a prior authorisation denial. Different form, different route, different deadline.

How old is the column and roughly how many injections has it seen?

Why two honest labs report different numbers on the same vial.

Start with the gradient. A shallower slope holds compounds on the column longer and usually separates close-eluting species better. A steeper one gets you a faster run and a fatter peak. If a related substance elutes near the main peak, one method resolves it and reports it separately, the other absorbs part of it into the main peak.

Then integration. Where the baseline is drawn under a shoulder is a decision made by a person or by a piece of software configured by a person. It moves the number.

A point or two of spread between services on this assay is ordinary. Treating one lab as ground truth is how people end up in arguments with suppliers that neither side can win.

External review was the thing that finally worked. I did not know it existed until a thread on this board.

Correction: that study was in rodents. Worth stating explicitly since the thread has been reading it as clinical.

Documented eighteen months of what had been tried in a one-page table. That table was the appeal.

Bought a second-hand instrument and learned more in six months of fixing it than in three years of reading traces.